Preclinical testing of new drugs for tuberculosis: current challenges

被引：72

作者：

Lenaerts, Anne J. ^{[1
]}

DeGroote, Mary Ann ^{[1
]}

Orme, Ian M. ^{[1
]}

机构：

[1] Colorado State Univ, Mycobacteriol Res Lab, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA

来源：

TRENDS IN MICROBIOLOGY | 2008年 / 16卷 / 02期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1016/j.tim.2007.12.002

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The continuing global epidemic of tuberculosis, the increasing rate of multidrug resistant (MDR) tuberculosis and the more recent emergence of extensively drug resistant (XDR) tuberculosis are great causes for concern. A major international effort is currently underway to optimize current drug therapies and to discover new drugs that are active against these organisms. This effort has created a pipeline of new candidate drugs at various stages of preclinical and early clinical evaluations. Major challenges still exist, however, varying from the standardization and application of current animal models and their application to drug discovery and characterization to the fact that our knowledge about the basic biology of the MDR and XDR strains of Mycobacterium tuberculosis is minimal at best.

引用

页码：48 / 54

页数：7

共 70 条

[1] Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice [J].